Highlights NeuBase Therapeutics, Inc.

Equities

NBSE

US64132K2015

Delayed Nasdaq Other stock markets 21:30:00 10/05/2024 BST			5-day change	1st Jan Change
0.378 ^USD	-3.20%		-6.67%	-48.93%

03-26	Wall Street Set to Open Modestly Higher Tuesday Ahead Consumer Confidence Reading	MT
03-26	US Futures Trend Higher Ahead of Durable Goods, House Prices, Consumer Confidence Readings	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Decliners	03-26	MT
North American Morning Briefing : Tech in Focus on -2-	03-25	DJ
North American Morning Briefing : Stock Futures -2-	03-11	DJ
North American Morning Briefing : Traders Await -2-	02-26	DJ
NeuBase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
NeuBase Therapeutics, Inc. Presents Non-Human Primate Data Illustrating Stealth Editors Are Non-Immunogenic, Opening the Door to Redosing	29/06/23	CI
Reverse Split: 1 of 20	14/06/23	FA
Neubase Therapeutics, Inc. Announces Positive Preclinical Data Supporting the Capabilities of Stealth Editors	22/05/23	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2023	11/05/23	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	14/02/23	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	21/12/22	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	11/08/22	CI
NeuBase Therapeutics, Inc. Presents New Preclinical Data At ASGCT 2022 for Its Dm1 Program Demonstrating Wide Tissue Distribution and Supporting Differentiated Whole-Body Treatment Solution	17/05/22	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	12/05/22	CI
NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal	13/03/22	CI
NeuBase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	11/02/22	CI
NeuBase Therapeutics FY21 Net Loss Widens; Shares Edging Higher in Late Trade	23/12/21	MT
NeuBase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2021	23/12/21	CI
Neubase Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended June 30, 2021	13/08/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NeuBase Therapeutics, Inc.

Equities

NBSE

US64132K2015

Highlights

Filters